These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 34472234)

  • 1. Adherence to Oral Anticoagulant Medications.
    Shani M; Comaneshter D; Lustman A
    Isr Med Assoc J; 2021 Sep; 23(9):580-583. PubMed ID: 34472234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
    Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA
    BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
    Henk HJ; Cao F; Tuell K; Price K; Singh P; Mardekian J; Odell K; Patel C; Tan W; Sands GH; Singhal S; Trocio J; Vo L
    Curr Med Res Opin; 2018 Mar; 34(3):539-546. PubMed ID: 29235900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
    Tiew WJ; Wong VL; Tan VH; Tan YC; Lee EM
    Ann Acad Med Singap; 2020 Nov; 49(11):838-847. PubMed ID: 33381777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
    Willey V; Franchino-Elder J; Fu AC; Wang C; Sander S; Tan H; Kraft E; Jain R
    BMJ Open; 2018 Jun; 8(6):e020676. PubMed ID: 29961012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.
    Perreault S; de Denus S; White-Guay B; Côté R; Schnitzer ME; Dubé MP; Dorais M; Tardif JC
    Pharmacotherapy; 2020 Jan; 40(1):40-54. PubMed ID: 31758592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China.
    Xiang X; Cao Y; Sun K; Song J; Tian Y; Yin Q; Juan J; Hu Y
    Curr Med Res Opin; 2018 Feb; 34(2):255-261. PubMed ID: 29022745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study.
    Giner-Soriano M; Cortes J; Gomez-Lumbreras A; Prat-Vallverdú O; Quijada-Manuitt MA; Morros R
    Aten Primaria; 2020 Oct; 52(8):529-538. PubMed ID: 32788057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.